Capoten

Phase 3Small molecule

GSK

Capoten is one of 32 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid LeukemiaActive, not recruiting

Acute Myeloid LeukemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 3

5 2

Dalalone

CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Phase 3

1 3

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 4

Lenograstim

Sanofi

Phase 3

1 5

Experimental

Biogen

Phase 3

1 6

Caspofungin Acetate

Merck & Co.

Phase 3

1 7

AG-120

Institut de Recherches Internationales Servier

Phase 3

4 8

Valspodar

EEastern Cooperative Oncology Group

Phase 3

3 9

Salvage Chemotherapy

Daiichi Sankyo

Phase 3

1 10

Homoharringtonine

Ascentage Pharma Group Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia

Completed·—·Phase 3·NCT03389724·245 enrolled

Fasting Conditions1 trial

Bioequivalence Study Between Capoten Versus Captopril Reference Product in Healthy Adult Participants Under Fasting Conditions

Withdrawn· GSK logo

GSK·Phase 1·NCT04878315

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Capoten. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Capoten compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Capoten. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

Capoten

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Fasting Conditions1 trial

References

Drug Info

Quick Facts

Related News